September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Highlights from WCLC 2025: 31 Posts Not to Miss
Sep 8, 2025, 02:50

Highlights from WCLC 2025: 31 Posts Not to Miss

The 2025 IASLC World Conference on Lung Cancer is underway in Barcelona, Spain, bringing together the world’s leading experts in lung cancer and thoracic oncology. This annual conference serves as a critical forum for clinicians, researchers, and industry leaders to explore the latest scientific discoveries, innovative treatments, and emerging trends in lung cancer care.

Attendees are engaging in high-level discussions, interactive workshops, and cutting-edge presentations, fostering collaboration and driving forward global efforts to improve outcomes for patients affected by lung cancer.

Our team at OncoDaily has selected a few posts from WCLC 2025 that you should not miss!

Shankar Siva:

“An unrelenting innovator in the field of Lung Cancer, Dr Suresh Senan received the James D. Cox Lectureship award and speaks about “Lung SABR 2.0″ at IASLC WCLC2025 – a great mentor to many and leader…. well deserved.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Triparna Sen:

“Honored to join the IASLC Board of Directors alongside my friend, collaborator, and co-author Hideto Horinouchi. Grateful to represent a truly multidisciplinary and global lung cancer community- united in advancing care, research, and hope. Let’s keep pushing the boundaries, together. ”

Gerry Hanna:

“Huge privilege to be back stage with WCLC25 Co-Chair Dr Jarushka Naidoo
during the opening plenary this afternoon in Barcelona Jarushka – we’re fiercely proud of you representing #Irish Oncology on this global stage.”

WCLC 2025

Luis E. Raez:

“Very successful IASLC Latin America session at WCLC 2025 discussing very relevant challenges from lung cancer screening to molecular testing, Lucia Viola, Edgardo Santos, Christian Rolfo, Oscar Arrieta.

Highlights from WCLC 2025: 31 Posts Not to Miss

Estela Rodriguez:

“WCLC25 E4512 (alchemist) Ph3 trial of crizotinib in adjuvant setting for stage II-III ALK+ NSCLC post chemo.

Although a negative study in DFS, and better alternatives (alectinib- ALINA) in adjuvant setting: still an important cooperative trial that took 10 yrs to complete, 7,345pts screened at a time when biomarker testing was not standard. Excellent discussion by Jessica J Lin.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Herbert Loong:

“Congrats, Lawson Eng of University Health Network, for being awarded the IASLC Lectureship in Tobacco Control And Smoking Cessation.

Super proud of what you have been working on and looking forward to your lecture!”

Highlights from WCLC 2025: 31 Posts Not to Miss

Jarushka Naidoo:

“IASLC Awards Luncheon Congrats to PhD Fellow David O’Reilly on his Adi Gazdar grant Thanks to colleagues and collaborators who supported him, and his work on liquid biopsy and exhaled breath biomarkers of chemo-IO.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Narjust Florez:

“In 2019 I wrote a controversial letter with 3 other junior members to have a women in thoracic oncology meeting at WCLC … Many things happened but this amazing woman had my back the whole time Congratulations Dr. Peters.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Triparna Sen:

“Last night at the IASLC Board of Directors dinner connected with my fellow Buckeye and global leader in lung cancer treatment David Carbone. Grateful to have him as a collaborator at Ohio State Medical Oncology as we work together to advance science and improve patient outcomes.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Antonio Calles:

“Neoadjuvant chemo adds nothing to osimertinib in terms of ctDNA clearance or pathological responses in resectable EGFR mutant lung cancer (neoADAURA trial). In my mind, this somehow conflicts with the results from FLAURA -2 in the metastatic setting, where the addition of chemo to osimertinib improves clinical outcomes. Is because different biology (eg., less clonality in smaller tumors?) Thoughts?”

Biagio Ricciuti:

“Neoadjuvant chemo-ICI may help refine treatment strategies for patients with borderline or unresectable stage III NSCLC. At WCLC25, our study was part of a session highlighting converging data that upfront chemo-immunotherapy may expand surgical options in stage III NSCLC.

Hidehito Horinouchi:

“IASLC WCLC25: Meet Happy to meet Triparna Sen.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Alessio Cortellini:

“Even though he was somehow mocking me, we are proud of our friend Biago Ricciuti, showing how IASLC grants helped shaping his career at the young Investigator workshop WCLC2025.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Sewanti Limaye:

“India shining bright at WCLC2025 IASLC Barcelona

Proud moment for India at the awards function hosted by brilliant Patel Oncology
Congratulation.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Shankar Siva:

“Trying to solve the lung cancer scientific world’s problems at WCLC25 one abstract at a time – searching for more radiation oncology to balance the discussion with these giants of CTSurgSocMedNetwork, Brendon Stiles, Biniam Kidane.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Jarushka Naidoo:

“Super proud of nurse specialist Ornagh Kestell for her incredibly thoughtful talk on how to navigate difficult conversations in LC care Great to showcase one of our patient advocates for Lung Health Check Ireland. Congrats.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Shankar Siva:

“An unrelenting innovator in the field of lung cancer , Dr Suresh Senan received the James D. Cox Lectureship award and speaks about “Lung SABR 2.0″ at IASLC WCLC2025 – a great mentor to many and leader…. well deserved ”

Eric K. Singhi:

“Sequencing absolutely matters in metastatic EGFR+ NSCLC. Even with advances like combination therapy, 26–31% of these often younger, fit patients with EGFR+ disease never make it to 2L treatment.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Christian Rolfo:

“Very excited to meeting the team of the Japan Lung Cancer Society at WCLC25 looking forward to collaborate in educational programs with ISLB and Ohio State Medical Oncology.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Cristiane D Bergerot:

“Words matter WCLC25.

The new IASLC Language Guide offers best practices for presentations and abstracts, encouraging thoughtful, accurate, and stigma-free communication in lung cancer.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Triparna Sen:

“So proud of the IASLC Academy mentees. After months of dedication and hard work, it is inspiring to see their projects come to life with such success. So deserving of this award and recognition. The future of lung cancer research and treatment is in great hands. Grateful to be a mentor on this journey and especially proud to share this moment with our own mentee from the team. Thank you, Christian Rolfo and Rami Manochakian, for the opportunity!”

Highlights from WCLC 2025: 31 Posts Not to Miss

Christian Rolfo:

“Very happy to see Dr Andrea Wolf awarded at WCLC25 for her work on mesothelioma. Very honored to have worked together in Mount Sinai. Excellent surgeon and great colleague!”

Highlights from WCLC 2025: 31 Posts Not to Miss

Coral Olazagasti:

“IASLC WCLC then (2019) vs now (2025) with Narjust Florez

From our first meeting to a mentee/mentor relationship, manuscripts, grants, orals, and best of all friendship We have come full circle”

Highlights from WCLC 2025: 31 Posts Not to Miss

Oncogene Cancer Research:

“Dr David Blanchard, Gustave Roussy, presents the latest FLAURA2 IASLC WCLC25. Great to see The separation curve and string results. Staying on our first line targeted therapy is key. How do we stratify which patients would be best for this approach?”

Charu Aggarwal:

“Terrific lecture by Dr. Wolf- what a well deserved honor to receive the Robert Ginsberg Award.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Fred R. Hirsch:

“So proud to see my colleague, Dr. Andrea Wolf being honored and receiving a well deserved award at the World Lung Cancer Conference in Barcelona!”

Highlights from WCLC 2025: 31 Posts Not to Miss

Eric K. Singhi:

“FULL house at the WCLC25 plenary this morning as we await the final overall survival update from FLAURA2. The looming question: how will this update shape our conversations with patients newly diagnosed with EGFR+ mNSCLC?”

Highlights from WCLC 2025: 31 Posts Not to Miss

Florez Lab:

“Poster 1480 At WCLC25,

Lauren Kiel presents: The Journey to a Lung Cancer Diagnosis (LEAD Study)

Sept 9 | 10:00 AM | Exhibit Hall

Findings: 1 in 3 pts reported diagnostic delays (50% younger vs 30% older); 3 women had symptoms first misattributed to anxiety.”

Highlights from WCLC 2025: 31 Posts Not to Miss

Matthew Smeltzer:

“WCLC25 early career workshop words of wisdom from Narjust Florez, Jonathan Spicer.

Do what you love, find a good environment, find good mentors, and have work-life balance. Be curious and keep it fun!”

Highlights from WCLC 2025: 31 Posts Not to Miss

Read Part 1 of WCLC25 Highlights on OncoDaily.

Highlights from WCLC 2025: 31 Posts Not to Miss